Actinium Pharmaceuticals, Inc.

348 articles about Actinium Pharmaceuticals, Inc.

• Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy

  11/4/2021

  Actinium Pharmaceuticals, Inc., a leader in the development of targeted radiotherapies for patients with unmet needs, announced that the Phase 1 trial studying Actimab-A with the salvage chemotherapy CLAG-M in patients with relapsed or refractory acute myeloid leukemia who are fit for intensive therapy has completed the planned dose escalation and patient enrollment.

• Actinium Announces Two Abstracts Highlighting Combinations of CD47 Targeting Immunotherapy with Targeted Radiotherapies in Solid Tumors and Blood Cancers Accepted for Presentation at Society for Immunotherapy for Cancer (SITC) Conference

  10/1/2021

  Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), today announced that two abstracts featuring targeted radiotherapies in combination with CD47 antibody immunotherapy for solid tumor and hematologic indications have been accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021).

• Actinium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29th

  9/28/2021

  Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference, which is being held from September 27th to 30th.

• Actinium Announces Expansion of R&D Team and Facilities to Accelerate Research Programs Focused on Solid Tumors and Novel Combinations with Checkpoint Inhibitors and Radioconjugates

  9/27/2021

  Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple updates on its R&D capabilities

• Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and Commercial Officer, New Chief Medical Officer and Vice President, Patent and Legal Counsel

  9/23/2021

  Actinium Pharmaceuticals, Inc. announced multiple senior leadership appointments including Arun Swaminathan, Ph.D., as Chief Business and Commercial Officer, Paul Diamond, Ph.D., as Vice President, Patent and Legal Counsel and Avinash Desai, M.D., who previously served as Executive Vice President, Clinical Development, Operations and Medical Affairs, to the position of Chief Medical Officer, effective immediately.

• Actinium to Present at Four Upcoming Investor Conferences

  9/20/2021

  Actinium Pharmaceuticals, Inc. today announced that it will present at four upcoming investor conferences.

• Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B

  9/15/2021

  Actinium Pharmaceuticals, Inc. today announced that it has completed enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B.

• Actinium Pharmaceuticals Announces Inclusion in Russell Microcap® Index

  6/28/2021

  Actinium Pharmaceuticals, Inc. announced today that it will be added to the Russell Microcap ®  Index at the conclusion of the 2021 Russell indexes annual reconstitution.

• Actinium Further Strengthens Patent Portfolio with International IP Covering the Composition and Methods of Administration of Iomab-B Antibody Radiation Conjugate in the EU and Japan

  6/17/2021

  Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its intellectual property portfolio around its lead Phase 3 candidate, Iomab-B, has been further strengthened internationally. In the EU, Actinium has been issued a patent covering the composition and methods administration of Iomab-B, an Antibody Radiation Conjugate (ARC) comprised of apamistamab

• Actinium Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting

  6/3/2021

  Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that three abstracts highlighting data and findings from the Company's pivotal Phase 3 SIERRA trial for lead program Iomab-B, have been accepted for 2 oral and 2 poster presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting,

• Actinium to Participate in the Cell &Gene Meeting on the Mediterranean

  3/31/2021

  Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Cell & Gene Meeting on the Mediterranean, which is being held virtually April 6 – 9, 2021,

• Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AML

  3/25/2021

  Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that initial patient enrollment in the second dose cohort in the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in fit and unfit patients with relapsed or refractory Acute Myeloid Leukemia (r/r AML) has been completed

• Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy

  3/24/2021

  - CAR T-cell therapy manufacturing commenced with Iomab-ACT conditioning and patient treatment scheduled for early Q2:2021 - Clinical proof-of-concept data expected in 2H:2021 from first of its kind trial funded by NIH STTR grant

• Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC

  3/11/2021

  - Positive preclinical data support continued development with strong potential in bone marrow transplant, adoptive cell therapy and gene therapy applications - Potent alpha emitter Actinium-225 targeted to CD45 cells demonstrates positive biodistribution profile and dose-dependent conditioning capabilities

• Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer

  3/3/2021

  - Mr. Kubik joins Actinium with over 25 years of experience in transformative and award-winning BD and M&A transactions - Proven deal making abilities in the empowered antibody, biologics and gene therapy fields strongly suited to Actinium's AWE technology platform and Antibody Radiation Conjugates for targeted conditioning

• Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference

  3/2/2021

  Actinium Pharmaceuticals, Inc.   (NYSE AMERICAN: ATNM) ("Actinium") today announced that management will participate in the H.C. Wainwright (HCW) Global Life Sciences Conference, which is being held digitally March 9-10, 2021 .

• Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting

  2/11/2021

  - TCT conference visibility bolsters strong momentum as SIERRA nears full enrollment following recent positive interim analysis - Strong results from 75% of patient enrollment highlighted in CME events, oral presentations and investigator interactions at TCT

• Actinium Announces Participation in BIO CEO & Investor Digital Conference

  2/10/2021

  Actinium Pharmaceuticals, Inc.   (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that management will participate in the BIO CEO & Investor conference, which is being held digitally February 16 – 18, 2021.

• 

  JPM2021, Day 3: Sanofi, Jazz Pharma, Replimune and More

  1/14/2021

  Here’s a look at some of the stories that emerged from the conference on Wednesday.

• Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies

  1/13/2021

  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas") to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology platform.